USP18通过其去泛素化活性对抗肝脂肪变性和胰岛素抵抗
研究报道去泛素化酶家族成员USP18在非酒精性脂肪性肝炎患者和高脂饮食或遗传性肥胖小鼠肝脏中表达下调;肝细胞特异性USP18转基因小鼠在高脂饮食下脂质代谢和胰岛素敏感性改善,而USP18敲除小鼠肝脂肪变性和糖代谢紊乱加重;机制上USP18与TAK1相互作用并去泛素化TAK1,抑制TAK1激活及下游JNK和NF-κB信号通路。
要点
- USP18在非酒精性脂肪性肝炎患者和高脂饮食或遗传性肥胖小鼠肝脏中表达下调。
- 肝细胞特异性USP18转基因小鼠在高脂饮食下脂质代谢和胰岛素敏感性改善。
- USP18与TAK1相互作用并去泛素化TAK1,抑制TAK1激活及下游JNK和NF-κB信号通路。
核心结论
- USP18与TAK1结合并去泛素化TAK1,从而对抗肝脂肪变性、胰岛素抵抗和炎症反应。
研究设计与样本
- 研究检测了非酒精性脂肪性肝炎患者和High-fat diet(HFD)诱导或遗传性肥胖小鼠肝脏中USP18的表达,并利用肝细胞特异性USP18转基因小鼠和肝细胞特异性USP18敲除小鼠在高脂饮食下观察表型。
主要发现
- USP18在非酒精性脂肪性肝炎患者和HFD诱导或遗传性肥胖小鼠肝脏中表达下调。
- HFD喂养的肝细胞特异性USP18转基因小鼠脂质代谢和胰岛素敏感性改善,而USP18敲除小鼠肝脂肪变性和糖代谢紊乱呈不利趋势。
- HFD喂养的USP18肝细胞特异性转基因小鼠伴随炎症反应受抑制,而USP18肝细胞特异性敲除小鼠炎症反应增强。
- 机制上USP18与TAK1相互作用并去泛素化TAK1,抑制TAK1激活及下游c-Jun N-terminal kinase和nuclear factor kappa B信号通路。
- HFD喂养的USP18肝细胞特异性敲除小鼠给予TAK1抑制剂后脂肪变性表型减轻且胰岛素信号高度激活。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Nonalcoholic fatty liver disease (NAFLD) is characterized by hepatic steatosis, impaired insulin sensitivity, and chronic low-grade inflammation. However, the pathogenic mechanism of NAFLD is poorly understood, which hinders the exploration of possible treatments. Here, we report that ubiquitin-specific protease 18 (USP18), a member of the deubiquitinating enzyme family, plays regulatory roles in NAFLD progression. Expression of USP18 was down-regulated in the livers of nonalcoholic steatohepatitis patients and high-fat diet (HFD)-induced or genetically obese mice. When challenged with HFD, hepatocyte-specific USP18 transgenic mice exhibited improved lipid metabolism and insulin sensitivity, whereas mice knocked out of USP18 expression showed adverse trends regarding hepatic steatosis and glucose metabolic disorders. Furthermore, the concomitant inflammatory response was suppressed in USP18-hepatocyte-specific transgenic mice and promoted in USP18-hepatocyte-specific knockout mice treated with HFD. Mechanistically, hepatocyte USP18 ameliorates hepatic steatosis by interacting with and deubiquitinating transforming growth factorβ-activated kinase 1 (TAK1), which inhibits TAK1 activation and subsequently suppresses the downstream c-Jun N-terminal kinase and nuclear factor kappa B signaling pathways. This is further validated by alleviated steatotic phenotypes and highly activated insulin signaling in HFD-fed USP18-hepatocyte-specific knockout mice administered a TAK1 inhibitor. The therapeutic effect of USP18 on NAFLD relies on its deubiquitinating activity because HFD-fed mice injected with active-site mutant USP18 failed to inhibit hepatic steatosis. CONCLUSION: USP18 associates with and deubiquitinates TAK1 to protect against hepatic steatosis, insulin resistance, and the inflammatory response. (Hepatology 2017;66:1866-1884).
引用
- An S, Zhao LP, Shen LJ, et al. USP18 protects against hepatic steatosis and insulin resistance through its deubiquitinating activity. Hepatology. 2017. PMID: 28718215. doi:10.1002/hep.29375
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。